Protagenic Therapeutics’ PT00114, a synthetic analog of TCAP, targets brain stress responses to address anxiety, depression, PTSD, and substance abuse disorders.
Bill Nichols leads Protagenic Therapeutics as President, overseeing strategy after joining in February 2026. He previously drove multi-billion-dollar commercial launches at bluebird bio, including LYFGENIA, ZYNTEGLO, and SKYSONA.
Dr. Armen serves as Executive Chairman of Protagenic Therapeutics, Chairman and CEO of Agenus Inc., and previously led Elan Corporation’s restructuring as board chairman.
Dr. Lauren Mueller directs preclinical research at Protagenic Therapeutics, leading development of PT00114 and the TCAP platform with expertise in behavioral neuroscience and pharmacology.
Dr. Robert B. Stein serves as Chief Medical Officer of Protagenic Therapeutics and Executive Vice President of R&D at MiMedx. He previously led Agenus Inc.’s R&D and remains a Senior Advisor for its research functions.
Not a classical antidepressant. Not a psychedelic. A new frontier. Protagenic Therapeutics is developing PT00114 (a first-in-class synthetic analog of TCAP) to treat anxiety, depression, PTSD and substance abuse disorders by targeting the brain's stress response system.